It has been a decent year for the biotech industry so far, buoyed by new drug approvals and positive regulatory/pipeline updates. The third-quarter earnings season has just kicked off, with most major biotech companies scheduled to report next week. The current momentum in the industry is mostly positive, with increasing R&D spending on lucrative areas such as obesity, gene-editing technologies and rare diseases.Companies in this volatile biotech industry continue to be in the spotlight as pharma/biotech go ...

Blueprint Medicines (BPMC) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on ...

Blueprint Medicines (BPMC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by th ...

CAMBRIDGE, Mass., Oct. 16, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, October 30, 2024, to report its third quarter 2024 financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 387547. A webcast of the call will also be available under "Events and Presentations" ...

CAMBRIDGE, Mass., Sept. 10, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming virtual investor conferences: Stifel 2024 Immunology and Inflammation Virtual Summit on Tuesday, September 17, 2024, at 2:00 p.m. ET. TD Cowen's Chronic Urticaria Summit on Friday, September 20, 2024, at 11:00 a.m. ET. A live webcast of each presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http:/ ...

A downtrend has been apparent in Blueprint Medicines (BPMC) lately. While the stock has lost 8.8% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support. While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future ...

Blueprint Medicines Corporation (BPMC) reported second-quarter 2024 adjusted loss of 80 cents per share, narrower than the Zacks Consensus Estimate of a loss of $1.28. The company had reported a loss of $2.19 per share in the year-ago quarter. Quarterly revenues of $138.2 million surpassed the Zacks Consensus Estimate of $105 million. Total revenues jumped almost 140% year over year. Despite the better-than-expected results, shares of Blueprint Medicines were down 7.4% on Aug 1 following the earnings announ ...

Financial Data and Key Metrics - Total revenues for Q2 2024 were $138.2 million, including $114.1 million in net product revenues from AYVAKIT and $24 million in collaboration, license, and other revenues [22] - AYVAKIT achieved $114.1 million in net product revenue, with $101.5 million in the US and $12.7 million ex-US, representing a year-over-year growth of more than 185% [9] - The company raised its AYVAKIT product revenue guidance to $435 million to $450 million for 2024, reflecting strong performance in the first half of the year [22] Business Line Performance - AYVAKIT's growth in the US was driven by new patient starts, low discontinuation rates, high compliance, and favorable commercial versus free goods mix [9] - The international team had an exceptional quarter, with the ISM launch underway in Germany and plans to expand to additional countries in 2025 [12] - The company expects continued strength in its international business, which is seen as an important contributor to future growth [12] Market Performance - The US market saw strong growth in AYVAKIT revenue, driven by expanding prescriber base and low discontinuation rates [9] - In Germany, the ISM launch is progressing well, with growing prescriber bases in both academic and community settings [12] - The company anticipates further international expansion, particularly in Europe, where pricing and reimbursement negotiations are ongoing [58] Company Strategy and Industry Competition - The company is focused on building a franchise in mast cell disorders with AYVAKIT, elenestinib, and BLU-808, targeting a multibillion-dollar market opportunity [18] - BLU-808, a wild-type KIT inhibitor, has entered clinical trials, with initial data expected early next year, potentially impacting a range of mast cell diseases [7][19] - The company is also advancing its cell cycle inhibition strategy, with BLU-222 and targeted protein degradation platforms, aiming to address unmet medical needs in oncology [20] Management Commentary on Operating Environment and Future Outlook - Management expressed strong confidence in AYVAKIT's long-term revenue potential, citing its unique value proposition and positive reception among physicians, patients, and payers [5][6] - The company highlighted the importance of patient compliance and long-term therapy duration as key drivers of future revenue growth [10] - Management noted that the chronic burden of ISM is often underappreciated and emphasized the need to redefine treatment expectations for patients and providers [15] Other Important Information - The company has $868.5 million in cash on hand, providing financial flexibility to invest in innovation and long-term growth [24] - Research and development expenses and SG&A expenses are expected to remain relatively flat for the remainder of the year [24] - The company is focused on driving long-term shareholder value through the successful launch of AYVAKIT and disciplined expense management [24] Q&A Session Summary Question: Quarterly dynamics and impact of Part D redesign on AYVAKIT launch [26] - Management noted seasonal dynamics in patient starts, with potential delays during vacation and holiday periods, but emphasized that the opportunity remains strong [28][29] - The proportion of free goods has stabilized at just under 20%, with no significant changes expected for the rest of the year [30] Question: Eligibility for AYVAKIT and long-term patient eligibility trends [33] - Providers are broadening their view of who is an appropriate patient for AYVAKIT, with a trend towards treating patients with fewer but impactful symptoms [34][35] - The company believes the prevalence of ISM may be underestimated, potentially leading to a larger patient population than initially thought [37] Question: Growth rate and potential for AYVAKIT to exceed $2 billion peak revenue [39] - Management reiterated confidence in AYVAKIT's peak revenue potential, citing strong year-over-year growth and expanding patient eligibility [41][43] - The company is monitoring factors such as broadening patient eligibility and increasing diagnosed patient numbers to assess potential for higher peak revenue [44] Question: Treatment duration and refill rates for AYVAKIT [47] - Patients on AYVAKIT are trending towards long-term therapy, with low discontinuation rates and high compliance, consistent with a multiyear duration of therapy [47][48] Question: Prescriber base expansion and strategy for AYVAKIT [50] - The prescriber base for AYVAKIT is expanding beyond the initial target of 400 physicians, with increasing adoption across hematologists, oncologists, and allergists [50][51] Question: Discontinuation rates and financial sustainability of BLU-808 development [53] - Discontinuation rates for AYVAKIT are very low, with patients staying on therapy for long durations [54] - The development of BLU-808 is factored into the company's financial guidance, with initial data expected to be a significant inflection point [56][57] Question: International expansion plans for AYVAKIT [58] - The company is focused on expanding AYVAKIT's presence in international markets, with ISM launches expected in additional countries in 2025 [58] Question: Spectrum of disease severity and patient eligibility for AYVAKIT [60] - The company is seeing a broadening of patient eligibility for AYVAKIT, with providers increasingly treating patients with less severe symptoms [63][64] Question: Biomarkers and metrics for BLU-808 healthy volunteer study [62] - The healthy volunteer study for BLU-808 will focus on safety, pharmacokinetics, and pharmacodynamics, with data expected to inform the breadth of its application [66] Question: Net pricing trends and revenue growth drivers for AYVAKIT [69] - There have been no quarter-over-quarter net pricing increases for AYVAKIT, with revenue growth driven by volume rather than price [70] Question: Prescriber trends in academic vs. community centers [72] - Prescribing trends for AYVAKIT are strong across both academic and community settings, with deepening adoption among experienced prescribers [73] Question: Differentiation of elenestinib and timeline for pivotal study [75] - Elenestinib, a next-generation KIT D816V inhibitor, is being developed with a focus on clinical differentiation in ISM, with Part 2 of the HARBOR study expected to begin by year-end [76] Question: Free drug dynamics and dose escalation trends for AYVAKIT [78] - The proportion of free goods has stabilized, with no significant changes expected for the rest of the year [81] - The majority of ISM patients start at 25 mg, with limited utilization of higher doses [82] Question: Business development strategy and challenges in HARBOR study enrollment [85] - The company is open to both inbound and outbound business development opportunities, with a focus on advancing its mast cell disorder franchise [86][87] - No major challenges are expected in enrolling patients for the HARBOR study, with international sites planned to support recruitment [89]

Table of Contents _____________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________ FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 _____________________________ BLUEPRINT MEDICINES CORPORATION (Exact Name of Regi ...

Second Quarter 2024 Financial Results AUG 1, 2024 Agenda INTRODUCTION AYVAKIT PERFORMANCE Kate Haviland Chief Executive Officer Philina Lee, PhD Chief Commercial Officer CORPORATE PROGRESS Christy Rossi Chief Operating Officer | --- | --- | --- | |-------|-------------------------|-------| | | | | | | | | | | | | | | Q2 2024 FINANCIAL | | | | PERFORMANCE | | | | | | | | Mike Landsittel | | | | Chief Financial Officer | | Not for promotional use 2 Forward-looking statements 3 This presentation contains forwa ...